Compare ADMA Biologics Inc (ADMA) vs Rockwell Automation (ROK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Rockwell Automation — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Rockwell Automation trades at $461.9 (market cap $52.18B). The key difference: Rockwell Automation is far larger — about 24.5× ADMA Biologics Inc's market cap, and Rockwell Automation pays a 1.18% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ROK | |
|---|---|---|
Market Cap | $2.13B | $52.18B |
Sector | Health | Industrials |
52-Week High | $20.38 | $495.08 |
52-Week Low | $7.60 | $328.67 |
Enterprise Value | $2.20B | $55.81B |
Dividend Yield | — | 1.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Rockwell Automation (ROK) trades at $468.9, down 0.59% today but near its 52-week high. The stock shows bullish technical momentum with consistent earnings beats in recent quarters. Revenue remains stable at $8.34B (2025), though net margins have softened to 10.41%. Recent news highlights AI infrastructure opportunities and product launches like FactoryTalk Orchestration, positioning ROK for industrial digital transformation growth.
Outlook remains positive with analyst consensus leaning toward Hold/Buy, targeting $463.86. Key opportunities include AI-driven industrial automation demand, while risks involve margin pressure and cyclical industry exposure. Valuation multiples (P/E 50.14) suggest premium pricing, requiring sustained earnings growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
